- Home
- RAPT
as 01-17-2025 4:00pm EST
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 59.1M | IPO Year: | 2019 |
| Target Price: | $6.00 | AVG Volume (30 days): | 9.1M |
| Analyst Decision: | Hold | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.79 - $27.35 | Next Earning Date: | 03-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest RAPT Therapeutics Inc. News
RAPT Breaking Stock News: Dive into RAPT Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
13 days ago
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
TipRanks
23 days ago
Rapt Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
MT Newswires
23 days ago
RAPT Therapeutics Shares Surge After HC Wainwright Upgrade
The Fly
23 days ago
Progressive, EverQuote upgraded: Wall Street's top analyst calls
MT Newswires
24 days ago
HC Wainwright Upgrades RAPT Therapeutics to Buy From Neutral, Price Target is $10
Pharmaceutical Technology
a month ago
RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement
MT Newswires
a month ago
Wells Fargo Raises RAPT Therapeutics' Price Target to $6 From $4, Overweight Rating Maintained
Compare RAPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RAPT RAPT Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.